William C. Gerth

1.8k total citations · 1 hit paper
21 papers, 1.4k citations indexed

About

William C. Gerth is a scholar working on Cardiology and Cardiovascular Medicine, Psychiatry and Mental health and Infectious Diseases. According to data from OpenAlex, William C. Gerth has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 6 papers in Psychiatry and Mental health and 4 papers in Infectious Diseases. Recurrent topics in William C. Gerth's work include Blood Pressure and Hypertension Studies (7 papers), Migraine and Headache Studies (5 papers) and Antifungal resistance and susceptibility (4 papers). William C. Gerth is often cited by papers focused on Blood Pressure and Hypertension Studies (7 papers), Migraine and Headache Studies (5 papers) and Antifungal resistance and susceptibility (4 papers). William C. Gerth collaborates with scholars based in United States, Canada and Sweden. William C. Gerth's co-authors include Panagiotis Mavros, Bengt Jönsson, Hans‐Georg Eichler, Sheldon X. Kong, George W. Carides, Michael Marentette, Paul R. Conlin, Stephen J. Boccuzzi, James M. Fox and Kelly B. Zarnke and has published in prestigious journals such as Diabetes Care, Kidney International and Clinical Therapeutics.

In The Last Decade

William C. Gerth

21 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

2004 623 citations Hans‐Georg Eichler, Sheldon X. Kong et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William C. Gerth United States	16	455	413	167	165	153	21	1.4k
Jacques LeLorier Canada	13	323 0.7×	526 1.3×	169 1.0×	262 1.6×	434 2.8×	24	1.8k
Luca Degli Esposti Italy	20	540 1.2×	295 0.7×	190 1.1×	300 1.8×	299 2.0×	200	1.7k
Joyce Lii United States	21	214 0.5×	369 0.9×	163 1.0×	422 2.6×	260 1.7×	54	1.6k
P. Ricordeau France	26	507 1.1×	276 0.7×	489 2.9×	98 0.6×	386 2.5×	69	2.4k
Teresa N. Harrison United States	21	501 1.1×	154 0.4×	119 0.7×	158 1.0×	186 1.2×	79	1.5k
Vincent J. Willey United States	23	372 0.8×	483 1.2×	201 1.2×	144 0.9×	552 3.6×	91	1.8k
Sudeep Karve United States	20	203 0.4×	243 0.6×	321 1.9×	502 3.0×	106 0.7×	63	1.5k
H. Allemand France	28	315 0.7×	196 0.5×	525 3.1×	85 0.5×	355 2.3×	88	2.1k
Stephen F. Derose United States	24	312 0.7×	349 0.8×	186 1.1×	137 0.8×	474 3.1×	57	2.0k
Winnie W. Nelson United States	29	1.3k 2.9×	303 0.7×	349 2.1×	212 1.3×	452 3.0×	113	2.8k

Countries citing papers authored by William C. Gerth

Since Specialization

Citations

This map shows the geographic impact of William C. Gerth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Gerth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Gerth more than expected).

Fields of papers citing papers by William C. Gerth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Gerth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Gerth. The network helps show where William C. Gerth may publish in the future.

Co-authorship network of co-authors of William C. Gerth

This figure shows the co-authorship network connecting the top 25 collaborators of William C. Gerth. A scholar is included among the top collaborators of William C. Gerth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Gerth. William C. Gerth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gerth, William C., Stephen Betschel, & Arthur S. Zbrozek. (2014). Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. Allergy Asthma and Clinical Immunology. 10(1). 23–23. 23 indexed citations

Wingard, John R., Helen Leather, William C. Gerth, et al.. (2007). Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. American Journal of Health-System Pharmacy. 64(6). 637–643. 29 indexed citations

Carides, George W., Shahnaz Shahinfar, Erik J. Dasbach, et al.. (2006). The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy. PharmacoEconomics. 24(6). 549–558. 11 indexed citations

Wingard, John R., et al.. (2005). Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis. Clinical Therapeutics. 27(6). 960–969. 25 indexed citations

Yu, Donghui, Josh F. Peterson, Diane L. Seger, William C. Gerth, & David W. Bates. (2005). Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiology and Drug Safety. 14(11). 755–767. 42 indexed citations

Burgess, Ellen, George W. Carides, William C. Gerth, Michael Marentette, & Isabelle Chabot. (2004). Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.. PubMed. 20(6). 613–8. 15 indexed citations

Gerth, William C., et al.. (2004). Productivity Cost Benefit to Employers of Treating Migraine With Rizatriptan: A Specific Worksite Analysis and Model. Journal of Occupational and Environmental Medicine. 46(1). 48–54. 17 indexed citations

Eichler, Hans‐Georg, Sheldon X. Kong, William C. Gerth, Panagiotis Mavros, & Bengt Jönsson. (2004). Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?. Value in Health. 7(5). 518–528. 623 indexed citations breakdown →

Slavin, Monica A., et al.. (2003). Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. International Journal of Infectious Diseases. 8(2). 111–120. 48 indexed citations

10.

Herman, William H., Shahnaz Shahinfar, George W. Carides, et al.. (2003). Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease. Diabetes Care. 26(3). 683–687. 61 indexed citations

11.

Lambert, Jean, et al.. (2002). Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial.. PubMed. 9(3). 158–64. 15 indexed citations

12.

Gerth, William C., Giuseppe Remuzzi, Giancarlo Viberti, et al.. (2002). Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney International. 62(82). S68–S72. 27 indexed citations

13.

Jönsson, Linus, William C. Gerth, & Johan Fastbom. (2002). The Potential Economic Consequences of Cognitive Improvement with Losartan. Blood Pressure. 11(1). 46–52. 5 indexed citations

14.

Gerth, William C.. (2002). Compliance and persistence with newer antihypertensive agents. Current Hypertension Reports. 4(6). 424–433. 39 indexed citations

15.

Bussone, Gennaro, Domenico D’Amico, Kathleen McCarroll, William C. Gerth, & Christopher R. Lines. (2002). Restoring Migraine Sufferers’ Ability to Function Normally: A Comparison of Rizatriptan and Other Triptans in Randomized Trials. European Neurology. 48(3). 172–177. 12 indexed citations

16.

Marentette, Michael, et al.. (2002). Antihypertensive persistence and drug class.. PubMed. 18(6). 649–56. 104 indexed citations

17.

Gerth, William C., George W. Carides, Erik J. Dasbach, W. Hester Visser, & Nancy C. Santanello. (2001). The Multinational Impact of Migraine Symptoms on Healthcare Utilisation and Work Loss. PharmacoEconomics. 19(2). 197–206. 77 indexed citations

18.

Conlin, Paul R., et al.. (2001). Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clinical Therapeutics. 23(12). 1999–2010. 143 indexed citations

19.

Dasbach, Erik J., Michael W. Rich, Robert Segal, et al.. (1999). The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure. Cardiology. 91(3). 189–194. 17 indexed citations

20.

Glick, Henry A., J.R. Cook, Bruce Kinosian, et al.. (1995). Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial. Journal of Cardiac Failure. 1(5). 371–380. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact